Alprenolol
Based on 9 publication(s) in Google Scholar
Alprenolol ((RS)-Alprenolol; dl-Alprenolol) is an orally active non-selective β-adrenoceptor antagonist and an antagonist of 5-HT1A and 5-HT1B receptors. Alprenolol is used as an anti-hypertensive, anti-anginal and anti-arrhythmic agent.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.94%
- CAS 番号: 13655-52-2
- 分子式: C15H23NO2
- 分子量:249.35
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Alprenolol
More- Nat Commun. 2026 Jan 16;17(1):1795. [Abstract]
- Nat Commun. 2020 Sep 25;11(1):4857. [Abstract]
- Nat Chem Biol. 2024 Jan;20(1):74-82. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Biochemistry. 2025 Aug 19;64(16):3585-3598. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 1:1227:123804. [Abstract]
- Sci Total Environ. 2024 May 13:933:173244. [Abstract]
- bioRxiv. 2020 Jan.
5-HT Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
|
5-HT1A Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
0.63 μM
Compound: 6
|
Antagonist activity at human 5HT1A expressed in BAF3 cells by fluorimetry analysis
Antagonist activity at human 5HT1A expressed in BAF3 cells by fluorimetry analysis
|
[PMID: 31303996] |
Alprenolol (i.p., 5 mg/kg) effectively blockes the anxiolytic effects of indorenate and ipsapirone but do not reduce the motor activity in adult male Swiss Webster mice[2].
Alprenolol (intravenous injection, 0.5 or 1.0 mg/kg) can decrease systolic pressure by a mean of 10 mm Hg, diastolic pressure by a mean of 10 mm Hg) and heart rate by 23 beats/min, as well as slightly reduce both myocardial and liver blood flows by mean of 17% and 15% respectively at a dose of 1.0 mg/kg in cats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 13655-52-2
-
性状 Solid
-
分子量 249.35
-
分子式 C15H23NO2
-
Color White to off-white
-
SMILES
OC(COC1=CC=CC=C1CC=C)CNC(C)C
-
別名
(RS)-Alprenolol; dl-Alprenolol
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
An artificial cell capable of signal transduction mediated by ADRB2 for the regulation of glycogenolysis. [Abstract]2026 Jan 16;17(1):1795. PMID: 41545427 -
Nat Commun
DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]2020 Sep 25;11(1):4857. PMID: 32978402 -
Nat Chem Biol
2024 Jan;20(1):74-82. PMID: 37580554 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Biochemistry
Biased Signaling and Its Role in the Genesis of Short- and Long-Acting β2-Adrenoceptor Agonists. [Abstract]2025 Aug 19;64(16):3585-3598. PMID: 40773134 -
J Chromatogr B Analyt Technol Biomed Life Sci
High-throughput screening of LogD by using a sample pooling approach based on the traditional shake flask method. [Abstract]2023 Jul 1:1227:123804. PMID: 37393793 -
Sci Total Environ
Comparison of in vitro membrane permeabilities of diverse environmental chemicals with in silico predictions. [Abstract]2024 May 13:933:173244. PMID: 38750756 -
溶剤 & 溶解度
DMSO : 50 mg/mL (200.52 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 4 mg/mL (16.04 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Himori N, et al. Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. [Content Brief]
[2]. Fernández-Guasti A, et al. Evidence for the involvement of the 5-HT1A receptor in the anxiolytic action of indorenate and ipsapirone. Psychopharmacology (Berl). 1990;101(3):354-8. [Content Brief]
[3]. Parratt JR, et al. Myocardial and haemodynamic effects of the beta-adrenoceptor blocking drug alprenolol (H56/28) in anaesthetized cats. Br J Pharmacol. 1969 Oct;37(2):357-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0104 mL | 20.0521 mL | 40.1043 mL | 100.2607 mL |
| 5 mM | 0.8021 mL | 4.0104 mL | 8.0209 mL | 20.0521 mL | |
| 10 mM | 0.4010 mL | 2.0052 mL | 4.0104 mL | 10.0261 mL | |
| 15 mM | 0.2674 mL | 1.3368 mL | 2.6736 mL | 6.6840 mL | |
| 20 mM | 0.2005 mL | 1.0026 mL | 2.0052 mL | 5.0130 mL | |
| 25 mM | 0.1604 mL | 0.8021 mL | 1.6042 mL | 4.0104 mL | |
| 30 mM | 0.1337 mL | 0.6684 mL | 1.3368 mL | 3.3420 mL | |
| 40 mM | 0.1003 mL | 0.5013 mL | 1.0026 mL | 2.5065 mL | |
| 50 mM | 0.0802 mL | 0.4010 mL | 0.8021 mL | 2.0052 mL | |
| 60 mM | 0.0668 mL | 0.3342 mL | 0.6684 mL | 1.6710 mL | |
| 80 mM | 0.0501 mL | 0.2507 mL | 0.5013 mL | 1.2533 mL | |
| 100 mM | 0.0401 mL | 0.2005 mL | 0.4010 mL | 1.0026 mL |
Alprenolol 関連分類
HY-B1517 関連分類
Powered by Bioz